Lundbeck expands the agreement with Teva to include marketing of Azilect in selected Asian countries
H. Lundbeck A/S announced it had expanded the agreement with Teva Pharmaceutical Industries Ltd. for Azilect® to cover six markets in Asia - China, South Korea, Hong Kong, Malaysia, Thailand and the Philippines.
The Asian market is becoming an increasingly important platform for Lundbeck, as the region experiences rapid growth within the CNS market. With the agreement Lundbeck gains access to six interesting Asian markets all expected to show significant growth within the Parkinson's disease market. Azilect® will be a significant growth driver of Lundbeck's Asian business in general, and especially for China and South Korea. The agreement comes on top of the recent grant of reimbursement in China on two of Lundbeck's key products, Cipralex® and Ebixa®.
As part of the agreement Lundbeck is responsible for conducting the clinical trials and preparing the application filings needed to gain a marketing authorisation in the individual markets. The first launch in one of the markets may potentially occur in approximately one year.
"With the new agreement with our partner Teva, we get an opportunity to expand our already successful work with Azilect®. The pharmaceutical markets in Asia, and the CNS market in particular, is undergoing rapid development, and we see this agreement as a possibility to further strengthen our commercial platform in this promising region," says Ole Chrintz, Senior Vice President, Commercial Operations at Lundbeck. "Azilect® is an important treatment option in an unsatisfied Parkinson's disease market and is the first medication that in clinical trials has shown an effect consistent with the possibility of disease modification in Parkinson's disease. We are glad that we will now be able to offer this effective treatment to the population in the Asian countries."
Specific financial terms remain undisclosed but Lundbeck will pay a share of net sales in the markets to Teva.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
List_of_subjects_in_Gray's_Anatomy:_III._Syndesmology
ClinPhone Group gains Champion status
2C_(psychedelics)
Medical_cannabis
AEterna Zentaris Announces Completion of Patient Enrollment for Ozarelix Phase II Trial in Benign Prostatic Hyperplasia
Structure of protective protein in the eye lens revealed - Heat shock proteins provide protection against cataracts
Acetate regulates immune cells for a precisely orchestrated immune defense - Similar to a pressure valve, which prevents the pressure from rising to critical levels, the regulation of immune cells by acetate prevents the immune reaction from overshooting
Congenital_absence_of_the_vas_deferens
Merck Intends to Submit Cladribine Tablets to Treat Multiple Sclerosis for Registration in Europe - Decision based on data available from the Cladribine Tablets clinical program and performed analyses
Decriminalization_of_non-medical_marijuana_in_the_United_States
Category:Pseudomonadales
